Bildkälla: Stockfoto

XVIVO Perfusion Q3: Continued overall growth with a mix of strong Abdominal sales and softer US Thoracic sales are soft due to the Delta (COVID) impact - Redeye

The immediate impact is likely to be somewhat negative as the Q3 confirms the risk of a negative Delta impact. Our view is that this is a temporary effect as we point to the existence of efficient COVID vaccines. Any pressure on XVIVO's valuation at this stage is probably a good opportunity to invest in XVIVO's future growth drivers.

The immediate impact is likely to be somewhat negative as the Q3 confirms the risk of a negative Delta impact. Our view is that this is a temporary effect as we point to the existence of efficient COVID vaccines. Any pressure on XVIVO's valuation at this stage is probably a good opportunity to invest in XVIVO's future growth drivers.
Börsvärldens nyhetsbrev
ANNONSER